-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下：CUBE公布第一季度营收为2.82亿美元（同比增长3.3%，超出市场预期400万美元），主要得益于收购。同店营收同比增长仅为0.2%，而净营业收入（NOI）下降了1.5%。每股FFO为0.63美元（同比下降1.6%），与市场预期一致，但不断上涨的人员成本（+7.2%）、广告支出（+54.4%）和房产税对利润率造成了压力。我们仍然认为，2026年下半年，由于新建项目过多造成的入住率压力将开始缓解，尤其是在表现不佳的阳光地带市场。管理层维持2026财年每股FFO 2.52美元至2.60美元的预期，以及同店营收增长-0.25%至+1.25%的预期。根据目前的趋势，我们预计同店支出将加速增长，净营业收入（NOI）将在2026年下半年转为负值。正如预期，入住率下降至89.3%（同比下降30个基点），但我们预计一旦新的供应压力缓解，入住率将有所改善。CUBE继续积极回购股票，金额达3300万美元，并通过收购和第三方管理业务的增长持续扩张。
Related Articles
Research
Research Alert: CFRA Reiterates Sell Opinion On Shares Of Hilton Worldwide Holdings Inc
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target by $9 to $293, or 32x our 2026 EPS estimate (unchanged) and in line with shares' five-year average forward multiple. We raise our 2026 EPS estimate to $9.16 from $8.88 and lower 2027's to $10.03 from $10.20. Following Q1 results that beat expectations and included raised guidance, we maintain our 2-STARS (Sell) rating. U.S. RevPAR performance broadened from primarily luxury and upper upscale segments to include more meaningful midscale contribution, which management attributes to the return of middle- and low-income consumers. However, we note Q1 results also included ADR deceleration, particularly among luxury hotels, which historically drive significant profit contribution. HLT's Q2 EBITDA guidance of $1,015-$1,035 million being below the $1,081 million consensus suggests luxury pricing power is weakening faster than midscale volume can offset. While the broadening demand trend is positive, we believe slowing luxury tailwinds limit upside at current valuation levels.
$HLT
Research
Research Alert: CFRA Maintains Buy Rating On Shares Of Universal Health Services
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $200 from $243, reflecting an 8.7x multiple of our 2026 EPS estimate, below peer multiples and a discount to UHS's five-year historical forward average of 11.9x. We lower our 2026 EPS forecast to $22.95 from $23.39 and cut our 2027 view to $25.48 from $25.67. Q1 inpatient volumes were flat on a same-facility basis, with seasonal headwinds from unfavorable winter weather and a milder flu/respiratory illness period. The recent expiration of ACA EPTCs also posed challenges, as UHS estimates a near 5% drop in ACA adjusted admissions relative to Q1 2025. UHS maintained its prior forecast of a 25%-30% decline in ACA exchange volumes during the full year, which represented around 6% of the acute care business adjusted admissions in 2025 and under 5% of the acute care segment revenues. UHS anticipates a $75M pre-tax earnings hit in 2026 from these developments, unchanged from prior guidance.
$UHS
Asia
Shenghe Resources' Q1 Profit Jumps 94%, Revenue Climbs 13%
Shenghe Resources' (SHA:600392) net profit attributable to shareholders in the first quarter jumped 94% to 327.3 million yuan from 168.3 million yuan a year earlier, according to a Shanghai bourse filing on Thursday.Earnings per share rose year on year to 0.1867 yuan from 0.0960 yuan.The Chinese rare earth miner's operating revenue climbed 13% to 3.38 billion yuan from 2.99 billion yuan in the previous year.
$SHA:600392